Warhound raises $200 million for genetically engineered working dogs

Warhound has emerged from stealth with $200 million from investors including In-Q-Tel, Sequoia and 8VC to develop genetically engineered dogs for military, law enforcement and emergency response work. The funding round gives the company a $1.2 billion valuation.

The venture grew out of discussions between Colossal Biosciences’ Ben Lamm and Anduril co-founder Palmer Luckey. Its intended uses include detecting bombs, conducting searches and carrying out other specialized tasks. Warhound said European suppliers account for more than 80% of U.S. military working dogs, with fewer than half suitable for service.

Lamm said his team collected cell lines from Belgian Malinois and German Shepherd dogs for a biobank. The plan is to edit genes to improve health and working abilities, including speed, agility and scent detection. Colossal holds equity in Warhound and licenses technology to it, while Luckey is a partner without an equity stake, Lamm said.

Anduril will provide hardware and software for protective vests, goggles and other equipment. Lamm described sensors on bulletproof vests that could relay information to handlers, with the aim of improving coordination and situational awareness.

Viagen, another Colossal-owned company, is helping Warhound clone the dogs. Lamm said the goal is for them to enter service within the next two years. Pricing has not been determined; prospective customers include the Department of Defense, police forces and first responders.

Lamm said Warhound has briefed government groups and that buyers would manage the dogs after military-style training. The company said it is working with guidance from the American Humane Society toward certification of its training program.